Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial
Top Cited Papers
- 1 June 2003
- journal article
- clinical trial
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 78 (6) , 687-695
- https://doi.org/10.4065/78.6.687
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Annual direct cost of urinary incontinenceObstetrics & Gynecology, 2001
- Effects of Tolterodine, Trospium Chloride, and Oxybutynin on the Central Nervous SystemThe Journal of Clinical Pharmacology, 2001
- Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT StudyMayo Clinic Proceedings, 2001
- Multiple Dose Pharmacokinetics of a New Once Daily Extended Release Tolterodine Formulation Versus Immediate Release TolterodineClinical Pharmacokinetics, 2001
- Dry mouth with conventional and controlled-release oxybutynin in urinary incontinenceObstetrics & Gynecology, 2000
- Clinical Efficacy and Safety of Tolterodine Compared to Oxybutynin and Placebo in Patients with Overactive BladderInternational Urogynecology Journal, 1999
- URINARY INCONTINENCE AND DEPRESSIONJournal of Urology, 1999
- ONCE DAILY CONTROLLED VERSUS IMMEDIATE RELEASE OXYBUTYNIN CHLORIDE FOR URGE URINARY INCONTINENCEJournal of Urology, 1999
- Economic costs of urinary incontinence in 1995Urology, 1998
- Efficacy and safety of tolterodine in patients with detrusor instability: a dose‐ranging studyBritish Journal of Urology, 1998